Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases-Reference-Cited by-同舟云学术

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Published:2018-03 Issue:3 Volume:29 Page:669-680
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Turner N.C.,Finn R.S.,Martin M.,Im S.-A.,DeMichele A.,Ettl J.,Diéras V.,Moulder S.,Lipatov O.,Colleoni M.,Cristofanilli M.,Lu D.R.,Mori A.,Giorgetti C.,Iyer S.,Bartlett C. Huang,Gelmon K.A.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/669/24530920/mdx797.pdf

Reference22 articles.

1. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options;Harb;Cancer Manag Res,2015

2. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology guideline;Rugo;JCO,2016

3. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Breast,2017

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 2.2017. https://www.nccn.org/store/login/login.aspx? ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (5 July 2017, date last accessed).

5. Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey;Lin;Cancer Med,2016

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy;Cancer Imaging;2024-07-09

2. Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial;Clinical and Translational Medicine;2024-05

3. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer;Cancer Gene Therapy;2024-02-26

4. CDK4/6 inhibitors in lung cancer: current practice and future directions;European Respiratory Review;2024-01-31

5. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16